Secukinumab (Synonyms: AIN457)

Name: Secukinumab
Brand: MedChemExpress
SKU: HY-P9927
Rating: 5.0 (8 reviews)

Cat. No.: HY-P9927 Purity: 98.9%: Data Sheet
COA

SDS

FAQs
Technical Support

Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.

For research use only. We do not sell to patients.

CAS No. : 1229022-83-6

Size	Stock	Quantity
Free Sample (100 μg)	Apply Now
Free Sample (100 μg)	Apply Now
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Secukinumab Featured Recommendations:

8 Publications Citing Use of MCE Secukinumab

Cell Proliferation/Viability Assay

RT-PCR

Cell Imaging/Staining

Histological Imaging/Staining

Cell Migration/Invasion Assay

: Secukinumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 22;16(1):6753. [Abstract]; The growth curve showed Secukinumab (IL-17a inhibitor, 0.0375-1.5 μg/mL; 48 h) had no impact on mouse tongue muscle cells (mTMCs), mouse tongue squamous cell carcinoma (mTSCC) cells and CaL27 cells proliferation.

: Secukinumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 22;16(1):6753. [Abstract]; Detecting the mRNA level of Desmin for skeletal marker, Col1a1, PDGFRβ, Vimentin and fibroblast activated protein (FAP) for CAFs marker by qRT-PCR to determine the optimal concentration of Secukinumab (0.075-1.5 μg/mL; 48 h) treated.

: Secukinumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 22;16(1):6753. [Abstract]; Representative H&E staining displayed the tumor size in saline-treated TSCC (n = 3 mice/group) and Secukinumab (10 mg/kg; i.p.; once weekly for 5 weeks)-treated TSCC (n = 3 mice/group, left panel). The tumor boundary is marked by black dashed lines. Scale bar = 100 μm. The results showed that Secukinumab significantly impeded tumor growth, resulting in markedly smaller tumor volumes.

: Secukinumab purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 May 15:770:152031. [Abstract]; CCK-8 assay for cell viability in MDA-MB-231 cells treated with si-NC, si-KIF20A, si-KIF20A + rhIL-17A (100 μg/L), or Secukinumab (10 μg/mL). RhIL-17A treatment rescued cell viability in si-KIF20A cells, while Secukinumab alone significantly reduced viability compared to si-NC.

: Secukinumab purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 May 15:770:152031. [Abstract]; The proliferation level of MDA-MB-231 cells was determined by the Edu staining assay (scale bars = 100 μm). RhIL-17A restored EdU-positive cell numbers in si-KIF20A cells, whereas Secukinumab (10 μg/mL; 24 h) decreased proliferation.

: Secukinumab purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 May 15:770:152031. [Abstract]; The migration of MDA-MB-231 cells was detected by wound healing assay (scale bars = 50 μm). si-KIF20A + rhIL-17A exhibited increased wound closure compared to si-KIF20A, while Secukinumab (10 μg/mL; 24 h)-treated cells showed reduced migration.

: Secukinumab purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 May 15:770:152031. [Abstract]; Transwell invasion assay (scale bars = 50 μm). RhIL-17A reversed the si-KIF20A-mediated reduction in invasive cells, and Secukinumab (10 μg/mL; 24 h) alone suppressed invasion similarly to si-KIF20A.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

Biological Activity
Purity & Documentation
References
Customer Review

Description

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target^[1]

IL-17A

In Vitro

Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A^[2].
Secukinumab (1 nM, 10 nM, and 100 nM) inhibits IL17A and IL17A/TNF a-induced increase in protein levels of IL6 in human astrocytes^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Gene ID

3605 [NCBI]

Accession

Q16552

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Molecular Weight

147.82 kDa

CAS No.

1229022-83-6

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Secukinumab]

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

Human IgG1 kappa

Biological Activity

Immobilized IL-17A Protein, Human (HEK293, His, HY-P70527) can bind Secukinumab. The EC₅₀ for this effect is 16.2 ng/mL.
Flow cytometric analysis of 1X10⁶ Jurkat cells with Secukinumab (HY-P9927, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

Purity & Documentation

Purity: ≥99.20%

Select Batch:

Data Sheet (260 KB) SDS (251 KB)

COA (232 KB)

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145. [Content Brief]

[2]. Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315. [Content Brief]

[3]. Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-735. [Content Brief]

Secukinumab Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Secukinumab1229022-83-6AIN457AIN 457AIN-457Interleukin RelatedILpsoriasisfirst-in-classselectiveneutralizesinterleukinarthritisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Secukinumab (Synonyms: AIN457)

Customer Review

Secukinumab Featured Recommendations:

Secukinumab Related Antibodies

8 Publications Citing Use of MCE Secukinumab

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Interleukin Related Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Secukinumab Related Antibodies

Secukinumab Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report